Marieta Georgieva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marieta Georgieva has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Kaloyan Dobrinov Georgiev
Department of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, Medical University of Varna, 9000 Varna, Bulgaria
8 shared publications - Stanila Stoeva-Grigorova
Department of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, Medical University of Varna, 9000 Varna, Bulgaria
5 shared publications - Maya Radeva-Ilieva
Department of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, Medical University of Varna, 9000 Varna, Bulgaria
4 shared publications - Nadezhda Hvarchanova
Department of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, Medical University of Varna, 9000 Varna, Bulgaria
4 shared publications Kaloyan Georgiev
3 shared publicationsA. Georgieva
2 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, e215600
Novel psychoactive substances: clinical challenges and therapeutic approaches
Introduction : New psychoactive substances (NPS) constitute a dynamic and diverse class of compounds marked by ongoing structural changes and expanding variability. Recent trends encompass newly developed synthetic cannabinoids, designer benzodiazepine derivatives, emerging dissociative agents, next-generation psychedelics, and highly potent synthetic opioids, as well as semisynthetic and plant-based substances such as kratom. Aim : To examine current trends and emerging developments within the NPS landscape, with a particular focus on newly identified substances, their mechanisms of action, and the clinical risks they pose. Materials and methods : A narrative review of current scientific literature and toxicological data was performed. Relevant publications were identified through nonsystematic searches of PubMed, Scopus, and Web of Science, supplemented by reports from international early warning systems, with an emphasis on newly recognized classes of NPS, their structural derivatives, and their clinical management. Results : Recent advances in the field of NPS are marked by greater molecular variability, strong receptor activity, and unpredictable pharmacokinetic behavior. Many newly developed synthetic cannabinoids function as full CB1 receptor agonists-unlike traditional cannabinoids-leading to severe clinical outcomes such as seizures, psychosis, and cardiovascular disturbances. Novel benzodiazepine-like compounds exhibit considerable toxicity even at low doses, while emerging dissociative agents and psychedelics are linked to significant neuropsychiatric effects. Synthetic opioids constitute a particularly high-risk subgroup due to their exceptional potency and narrow therapeutic window, and certain fentanyl analogues can induce fatal respiratory depression at microgram levels. Conclusion : A key clinical concern is the frequent occurrence of polydrug use, alongside the limited ability of standard toxicology screens to detect many NPS, which necessitates the use of more advanced analytical approaches. Management remains largely supportive and nonspecific, and most therapeutic recommendations are extrapolated from conventional substance use disorders. Ongoing surveillance and timely updates of toxicological knowledge are crucial to address the rapidly evolving and highly dynamic NPS market.
- 11 November 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, e215600
Open AccessNovel psychoactive substances: clinical challenges and therapeutic approaches
Introduction : New psychoactive substances (NPS) constitute a dynamic and diverse class of compounds marked by ongoing structural changes and expanding variability. Recent trends encompass newly developed synthetic cannabinoids, designer benzodiazepine derivatives, emerging dissociative agents, next-generation psychedelics, and highly potent synthetic opioids, as well as semisynthetic and plant-based substances such as kratom. Aim : To examine current trends and emerging developments within the NPS landscape, with a particular focus on newly identified substances, their mechanisms of action, and the clinical risks they pose. Materials and methods : A narrative review of current scientific literature and toxicological data was performed. Relevant publications were identified through nonsystematic searches of PubMed, Scopus, and Web of Science, supplemented by reports from international early warning systems, with an emphasis on newly recognized classes of NPS, their structural derivatives, and their clinical management. Results : Recent advances in the field of NPS are marked by greater molecular variability, strong receptor activity, and unpredictable pharmacokinetic behavior. Many newly developed synthetic cannabinoids function as full CB1 receptor agonists-unlike traditional cannabinoids-leading to severe clinical outcomes such as seizures, psychosis, and cardiovascular disturbances. Novel benzodiazepine-like compounds exhibit considerable toxicity even at low doses, while emerging dissociative agents and psychedelics are linked to significant neuropsychiatric effects. Synthetic opioids constitute a particularly high-risk subgroup due to their exceptional potency and narrow therapeutic window, and certain fentanyl analogues can induce fatal respiratory depression at microgram levels. Conclusion : A key clinical concern is the frequent occurrence of polydrug use, alongside the limited ability of standard toxicology screens to detect many NPS, which necessitates the use of more advanced analytical approaches. Management remains largely supportive and nonspecific, and most therapeutic recommendations are extrapolated from conventional substance use disorders. Ongoing surveillance and timely updates of toxicological knowledge are crucial to address the rapidly evolving and highly dynamic NPS market.
- Open Access
- 6 April 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, 1-8
Probiotics and mental disorders
Neurodegenerative and neuropsychiatric disorders continue to pose significant public health challenges due to their progressive course, high prevalence, and substantial socioeconomic impact. Conventional therapies are often limited by pharmacoresistance, side effects, and suboptimal efficacy, emphasizing the need for complementary and integrative approaches. Emerging research underscores the pivotal role of the gut–brain axis (GBA) in neurological health, highlighting psychobiotics and specific probiotic strains with potential mental health benefits as promising adjunctive interventions. This review synthesizes current evidence on the GBA’s involvement in conditions such as Alzheimer’s disease, Parkinson’s disease, depression, and anxiety. We explore how psychobiotics may influence neuroinflammation, oxidative stress, and neurotransmitter signaling, thereby supporting cognitive function and emotional regulation. Findings from both preclinical and clinical studies are examined, including quality-of-life measures and neuropsychiatric comorbidities. Additionally, we discuss recent innovations, including precision psychobiotics, microbiota–drug interactions, and their implications for overlapping metabolic and neurodegenerative disorders.
- 6 April 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, 1-8
Open AccessProbiotics and mental disorders
Neurodegenerative and neuropsychiatric disorders continue to pose significant public health challenges due to their progressive course, high prevalence, and substantial socioeconomic impact. Conventional therapies are often limited by pharmacoresistance, side effects, and suboptimal efficacy, emphasizing the need for complementary and integrative approaches. Emerging research underscores the pivotal role of the gut–brain axis (GBA) in neurological health, highlighting psychobiotics and specific probiotic strains with potential mental health benefits as promising adjunctive interventions. This review synthesizes current evidence on the GBA’s involvement in conditions such as Alzheimer’s disease, Parkinson’s disease, depression, and anxiety. We explore how psychobiotics may influence neuroinflammation, oxidative stress, and neurotransmitter signaling, thereby supporting cognitive function and emotional regulation. Findings from both preclinical and clinical studies are examined, including quality-of-life measures and neuropsychiatric comorbidities. Additionally, we discuss recent innovations, including precision psychobiotics, microbiota–drug interactions, and their implications for overlapping metabolic and neurodegenerative disorders.
- 21 August 2025
- Published by Taylor & Francis
- p. 214-222
Aflatoxigenic Fungi
Aflatoxins, primarily produced by Aspergillus flavus and Aspergillus parasiticus, pose a significant health risk, particularly through contaminated foods like corn and peanuts. These toxins, categorized as carcinogens, contribute substantially to hepatocellular carcinoma, especially in regions with favorable climatic conditions for fungal growth. The biotransformation of Aflatoxin B1 (AFB1) in humans involves metabolic pathways leading to DNA adduct formation, oxidative stress, and subsequent cellular damage, highlighting the intricate mechanisms underlying carcinogenesis. Genetic variations, particularly in enzymes involved in AFB1 metabolism, influence susceptibility to aflatoxin-associated liver cancer. Biomonitoring of aflatoxin exposure in humans relies on identifying biomarkers like AFB1-albumin adducts and urinary metabolites. Strategies to mitigate aflatoxin-associated risks include dietary interventions, pharmacokinetic approaches, and vaccination against hepatitis B. Despite advancements, challenges persist in understanding individual variability in toxin response and developing effective preventive measures. Continued research leveraging advanced analytical tools and biomarker identification offers promise in combating aflatoxin-related diseases in affected regions worldwide.
- 21 August 2025
- Published by Taylor & Francis
- p. 214-222
Aflatoxigenic Fungi
Aflatoxins, primarily produced by Aspergillus flavus and Aspergillus parasiticus, pose a significant health risk, particularly through contaminated foods like corn and peanuts. These toxins, categorized as carcinogens, contribute substantially to hepatocellular carcinoma, especially in regions with favorable climatic conditions for fungal growth. The biotransformation of Aflatoxin B1 (AFB1) in humans involves metabolic pathways leading to DNA adduct formation, oxidative stress, and subsequent cellular damage, highlighting the intricate mechanisms underlying carcinogenesis. Genetic variations, particularly in enzymes involved in AFB1 metabolism, influence susceptibility to aflatoxin-associated liver cancer. Biomonitoring of aflatoxin exposure in humans relies on identifying biomarkers like AFB1-albumin adducts and urinary metabolites. Strategies to mitigate aflatoxin-associated risks include dietary interventions, pharmacokinetic approaches, and vaccination against hepatitis B. Despite advancements, challenges persist in understanding individual variability in toxin response and developing effective preventive measures. Continued research leveraging advanced analytical tools and biomarker identification offers promise in combating aflatoxin-related diseases in affected regions worldwide.
- Open Access
- 26 February 2025
- Published by Prof. Marin Drinov Publishing House of BAS (Bulgarian Academy of Sciences) in Proceedings of the Bulgarian Academy of Sciences
- Vol. 78 (2) , 261–268
Assessment of Antioxidant and Hepatoprotective Activity of Probiotic Food LDB-ST against Paracetamol-induced Liver Damage in Rats
Recently, the probiotics' therapeutic influence on different hepatic disorders has been established. Given the fact that free radicals are involved in the toxic liver injury pathogenesis, it was important to investigate whether the probiotic cocktail LDB-ST could be used as an antioxidant and a hepatoprotective agent. The antioxidant and hepatoprotective activity of the probiotic food in question against Paracetamol (PCM) induced liver injury in 24 male Wistar rats (divided into four groups, n=6) were evaluated. The PCM-treatment (1200 mg/kg b. w., p. o.) resulted in serious hepatotoxic injury and increase in alanine aminotransferase, aspartate aminotransferase, total bilirubin and gamma-glutamyl transferase levels. On the other hand, the animals pre-treated with LDB-ST (1600 mg/kg b. w., p. o.) for 60 days prior to PCM-gavaging, showed significant improvement of the biochemical markers. The methodical LDB-ST-treatment also led to maintaining the reduced glutathione level to 71% and also reduced malondialdehyde production by 14%. The conducted histopathological examination reaffirmed the hepatoprotective effect of the probiotic food against PCM-induced liver damage, as there was no fatty degeneration observed and fewer focal necrosis, acidophilic necrosis, and nonspecific granulomas established (vs. PCM-overdosed group). The oral long-term treatment with LDB-ST resulted in a significant protection against lipid peroxidation and oxidative stress in the applied animal model.
- 26 February 2025
- Published by Prof. Marin Drinov Publishing House of BAS (Bulgarian Academy of Sciences) in Proceedings of the Bulgarian Academy of Sciences
- Vol. 78 (2) , 261–268
Open AccessAssessment of Antioxidant and Hepatoprotective Activity of Probiotic Food LDB-ST against Paracetamol-induced Liver Damage in Rats
Recently, the probiotics' therapeutic influence on different hepatic disorders has been established. Given the fact that free radicals are involved in the toxic liver injury pathogenesis, it was important to investigate whether the probiotic cocktail LDB-ST could be used as an antioxidant and a hepatoprotective agent. The antioxidant and hepatoprotective activity of the probiotic food in question against Paracetamol (PCM) induced liver injury in 24 male Wistar rats (divided into four groups, n=6) were evaluated. The PCM-treatment (1200 mg/kg b. w., p. o.) resulted in serious hepatotoxic injury and increase in alanine aminotransferase, aspartate aminotransferase, total bilirubin and gamma-glutamyl transferase levels. On the other hand, the animals pre-treated with LDB-ST (1600 mg/kg b. w., p. o.) for 60 days prior to PCM-gavaging, showed significant improvement of the biochemical markers. The methodical LDB-ST-treatment also led to maintaining the reduced glutathione level to 71% and also reduced malondialdehyde production by 14%. The conducted histopathological examination reaffirmed the hepatoprotective effect of the probiotic food against PCM-induced liver damage, as there was no fatty degeneration observed and fewer focal necrosis, acidophilic necrosis, and nonspecific granulomas established (vs. PCM-overdosed group). The oral long-term treatment with LDB-ST resulted in a significant protection against lipid peroxidation and oxidative stress in the applied animal model.
- 31 July 2024
- Published by Bentham Science Publishers Ltd. in Current Traditional Medicine
- Vol. 10
A Study of the Effect of Bancha Green Tea Extract and Catechin Fraction on Sildenafil Pharmacokinetics in Rats
Background: Sildenafil is a drug that belongs to the group of phosphodiesterase-5 inhibitors. It is used in the treatment of erectile dysfunction and pulmonary arterial hypertension. Sildenafil undergoes metabolism in the liver by CYP3A4 and CYP2C9. Therefore, drug interactions may occur if sildenafil is taken simultaneously with CYP3A4 and CYP2C9 inhibitors such as green tea catechins. Objective: The aim of the present work was to analyze epigallocatechin-3-gallate (EGCG) and caffeine content in total extract and catechin fraction from Bancha green tea leaves as well as to assess their effect on sildenafil pharmacokinetics in rats. Methods: Animals received sildenafil alone and in combination with total Bancha green tea extract, catechin fraction or ketoconazole (a well-known CYP3A4 inhibitor). The plant extracts and the plasma concentrations of sildenafil were analyzed with high-performance liquid chromatography. Results: Administration of sildenafil after pretreatment of the rats with total extract and catechin fraction from Bancha green tea resulted in a statistically significant increase in Cmax, AUC0-t and AUC0-inf and a decrease in the volume of distribution and clearance of sildenafil compared to the control group. A significant increase in Cmax, AUC0-t and AUC0-inf of sildenafil was also observed after simultaneous intake of sildenafil and ketoconazole. Conclusion: Co-administration of sildenafil and the isolated Bancha green tea extracts led to a significant change in sildenafil pharmacokinetics in rats. Therefore, further, in vivo studies are necessary to clarify the exact mechanisms responsible for the interactions established as well as to evaluate the risk for clinically significant interactions in humans.
- 31 July 2024
- Published by Bentham Science Publishers Ltd. in Current Traditional Medicine
- Vol. 10
A Study of the Effect of Bancha Green Tea Extract and Catechin Fraction on Sildenafil Pharmacokinetics in Rats
Background: Sildenafil is a drug that belongs to the group of phosphodiesterase-5 inhibitors. It is used in the treatment of erectile dysfunction and pulmonary arterial hypertension. Sildenafil undergoes metabolism in the liver by CYP3A4 and CYP2C9. Therefore, drug interactions may occur if sildenafil is taken simultaneously with CYP3A4 and CYP2C9 inhibitors such as green tea catechins. Objective: The aim of the present work was to analyze epigallocatechin-3-gallate (EGCG) and caffeine content in total extract and catechin fraction from Bancha green tea leaves as well as to assess their effect on sildenafil pharmacokinetics in rats. Methods: Animals received sildenafil alone and in combination with total Bancha green tea extract, catechin fraction or ketoconazole (a well-known CYP3A4 inhibitor). The plant extracts and the plasma concentrations of sildenafil were analyzed with high-performance liquid chromatography. Results: Administration of sildenafil after pretreatment of the rats with total extract and catechin fraction from Bancha green tea resulted in a statistically significant increase in Cmax, AUC0-t and AUC0-inf and a decrease in the volume of distribution and clearance of sildenafil compared to the control group. A significant increase in Cmax, AUC0-t and AUC0-inf of sildenafil was also observed after simultaneous intake of sildenafil and ketoconazole. Conclusion: Co-administration of sildenafil and the isolated Bancha green tea extracts led to a significant change in sildenafil pharmacokinetics in rats. Therefore, further, in vivo studies are necessary to clarify the exact mechanisms responsible for the interactions established as well as to evaluate the risk for clinically significant interactions in humans.
- Open Access
- 9 January 2023
- Published by Taylor & Francis in Biotechnology & Biotechnological Equipment
- Vol. 37 (1) , 64-73
Cardio- and nephroprotective effects of fractions isolated from Lycium barbarum (goji berry) in models of cardio- and nephrotoxicity in rats
The aim of the present study was to identify agents that reduce the anthracyclines-induced cardiovascular and renal damage and have the potential to enhance their therapeutic effects. Three fractions of Lycium barbarum (Goji berry), pectin-free, polysaccharide and a combination of the two (1:1, w/w), were tested on rat models of doxorubicin (DOX)-induced cardio- and nephrotoxicity. They were administered p.o. as doses of 2 mg/kg. DOX was applied at a cumulative dose of 20 mg/kg (i.p.). Different biomarkers for cardiotoxicity (creatine kinase, creatine kinase-MB fraction, aspartate aminotransferase, lactate dehydrogenase), nephrotoxicity (creatinine, blood urea nitrogen, uric acid) and the serum potassium levels were evaluated. Histological analysis of hearts and kidneys was performed. The male Wistar rats treated only with DOX showed a drastic increase in all biomarkers for toxicity. Meanwhile, in all cohorts receiving simultaneously any of the plant fractions, the biomarkers for heart and kidney tissue damage were significantly reduced (p < 0.001 for uric acid; p < 0.01 for other parameters). Intriguingly, the pectin-free fraction and the combined one showed the most pronounced decrease in the indicators for toxicity. Histological findings also confirmed these observations, suggesting that the fractions in question need to be investigated as potential enhancers of anthracyclines’ pharmacodynamic effects.
- 9 January 2023
- Published by Taylor & Francis in Biotechnology & Biotechnological Equipment
- Vol. 37 (1) , 64-73
Open AccessCardio- and nephroprotective effects of fractions isolated from Lycium barbarum (goji berry) in models of cardio- and nephrotoxicity in rats
The aim of the present study was to identify agents that reduce the anthracyclines-induced cardiovascular and renal damage and have the potential to enhance their therapeutic effects. Three fractions of Lycium barbarum (Goji berry), pectin-free, polysaccharide and a combination of the two (1:1, w/w), were tested on rat models of doxorubicin (DOX)-induced cardio- and nephrotoxicity. They were administered p.o. as doses of 2 mg/kg. DOX was applied at a cumulative dose of 20 mg/kg (i.p.). Different biomarkers for cardiotoxicity (creatine kinase, creatine kinase-MB fraction, aspartate aminotransferase, lactate dehydrogenase), nephrotoxicity (creatinine, blood urea nitrogen, uric acid) and the serum potassium levels were evaluated. Histological analysis of hearts and kidneys was performed. The male Wistar rats treated only with DOX showed a drastic increase in all biomarkers for toxicity. Meanwhile, in all cohorts receiving simultaneously any of the plant fractions, the biomarkers for heart and kidney tissue damage were significantly reduced (p < 0.001 for uric acid; p < 0.01 for other parameters). Intriguingly, the pectin-free fraction and the combined one showed the most pronounced decrease in the indicators for toxicity. Histological findings also confirmed these observations, suggesting that the fractions in question need to be investigated as potential enhancers of anthracyclines’ pharmacodynamic effects.
- Open Access
- 1 January 2020
- Published by Wiley in BioMed Research International
- Vol. 2020 (1) , 4018412
Protective Effect of Methylxanthine Fractions Isolated from Bancha Tea Leaves against Doxorubicin‐Induced Cardio‐ and Nephrotoxicities in Rats
Doxorubicin is an anthracycline antibiotic that is used for the treatment of various types of cancer. However, its clinical usage is limited due to its potential life‐threatening adverse effects, such as cardio‐ and nephrotoxicities. Nonetheless, simultaneous administration of doxorubicin and antioxidants, such as those found in green tea leaves, could reduce cardiac and renal tissue damage caused by oxidative stress. The methylxanthine fraction isolated from Bancha tea leaves were tested in vitro for its antioxidant activity and in vivo for its organoprotective properties against doxorubicin‐induced cardio‐ and nephrotoxicities in a rat model. The in vivo study was conducted on male Wistar rats divided into 6 groups. Methylxanthines were administered at high (5 mg/kg body weight) and low (1 mg/kg body weight) doses, while doxorubicin was administered at a cumulative dose of 20 mg/kg body weight. Serum creatinine, uric acid, and urea concentrations, as well as serum enzyme levels (creatinine kinase (CK), creatinine kinase MB fraction (CK‐MB), aspartate aminotransferase (AST), and lactate dehydrogenase (LDH)) and electrolytes (Na+, K+, and Cl-), were analysed. In addition, histological analysis was performed to assess cardiac and renal tissue damage. The concomitant administration of Bancha methylxanthines and doxorubicin showed a dose‐dependent reduction in the serum biochemical parameters, indicating a decrease in the cardiac and renal tissue damage caused by the antibiotic. Histological analysis showed that pretreatment with methylxanthines at the dose of 5 mg/kg resulted in an almost normal myocardial structure and a significant decrease in the morphological kidney changes caused by doxorubicin exposure compared with the group that received doxorubicin alone. The putative mechanism is most likely related to a reduction in the oxidative stress caused by doxorubicin.
- 1 January 2020
- Published by Wiley in BioMed Research International
- Vol. 2020 (1) , 4018412
Open AccessProtective Effect of Methylxanthine Fractions Isolated from Bancha Tea Leaves against Doxorubicin‐Induced Cardio‐ and Nephrotoxicities in Rats
Doxorubicin is an anthracycline antibiotic that is used for the treatment of various types of cancer. However, its clinical usage is limited due to its potential life‐threatening adverse effects, such as cardio‐ and nephrotoxicities. Nonetheless, simultaneous administration of doxorubicin and antioxidants, such as those found in green tea leaves, could reduce cardiac and renal tissue damage caused by oxidative stress. The methylxanthine fraction isolated from Bancha tea leaves were tested in vitro for its antioxidant activity and in vivo for its organoprotective properties against doxorubicin‐induced cardio‐ and nephrotoxicities in a rat model. The in vivo study was conducted on male Wistar rats divided into 6 groups. Methylxanthines were administered at high (5 mg/kg body weight) and low (1 mg/kg body weight) doses, while doxorubicin was administered at a cumulative dose of 20 mg/kg body weight. Serum creatinine, uric acid, and urea concentrations, as well as serum enzyme levels (creatinine kinase (CK), creatinine kinase MB fraction (CK‐MB), aspartate aminotransferase (AST), and lactate dehydrogenase (LDH)) and electrolytes (Na+, K+, and Cl-), were analysed. In addition, histological analysis was performed to assess cardiac and renal tissue damage. The concomitant administration of Bancha methylxanthines and doxorubicin showed a dose‐dependent reduction in the serum biochemical parameters, indicating a decrease in the cardiac and renal tissue damage caused by the antibiotic. Histological analysis showed that pretreatment with methylxanthines at the dose of 5 mg/kg resulted in an almost normal myocardial structure and a significant decrease in the morphological kidney changes caused by doxorubicin exposure compared with the group that received doxorubicin alone. The putative mechanism is most likely related to a reduction in the oxidative stress caused by doxorubicin.
- 8 October 2019
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 41 (6) , 1555-1561
The role of the clinical pharmacist in the prevention of potential drug interactions in geriatric heart failure patients
Background The treatment of heart failure patients is very complex and includes lifestyle modification as well as different pharmacological therapies. Polypharmacy is very common in such patients and they are at increased risk of potential drug–drug interactions and associated effects such as poor adherence, compliance and adverse events. Objective The aim of the present study is to investigate retrospectively the prescribed pharmacotherapy of the hospital discharged heart failure patients for possible drug interactions. Settings Clinic for Cardiology of the “Saint Marina” University Hospital in Varna, Bulgaria. Method Lexicomp® Drug interaction software was used for screening potential drug–drug interactions. Logistic regression was applied to determine the odds ratio for the association between the age and number of drugs taken and the number of potential drug–drug interactions. Main outcome measure Incidence and type of pDDIs in geriatric heart failure patients. Results A retrospective study was conducted by reviewing the medical records of 248 selected heart failure patients for the prescribed medicines for a 1-year period (January 2015–December 2015). The total number of potential drug–drug interactions was 1532, or approximately 6.28 (± 4.72 SD) per one person. The range of prescribed drugs was between three and fourteen, 92% of them have been taking more than five medicines, an average of 7.12 (± 2.07 SD) per patient. The average age was 72.35 (± 10.16 SD). The results have shown stronger association between the number of drugs taken (more than 7) and the occurrence of potential drug–drug interactions (more than 10)—37.84 (95% CI 9.012–158.896, P ≤ 0.001). No statistically significant differences were found between age and occurrence of potential drug–drug interactions (more than 10)—1.008 (95% CI 0.441–2.308, P = 0.848). Conclusion The incidence of drug-drug interactions in heart failure patients is high. The clinical pharmacist, as a part of the multidisciplinary team, could reduce medication-related problems, such as drug interactions, and to optimize drug therapy by checking the treatment prescribed at the discharge of these patients.
- 8 October 2019
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 41 (6) , 1555-1561
The role of the clinical pharmacist in the prevention of potential drug interactions in geriatric heart failure patients
Background The treatment of heart failure patients is very complex and includes lifestyle modification as well as different pharmacological therapies. Polypharmacy is very common in such patients and they are at increased risk of potential drug–drug interactions and associated effects such as poor adherence, compliance and adverse events. Objective The aim of the present study is to investigate retrospectively the prescribed pharmacotherapy of the hospital discharged heart failure patients for possible drug interactions. Settings Clinic for Cardiology of the “Saint Marina” University Hospital in Varna, Bulgaria. Method Lexicomp® Drug interaction software was used for screening potential drug–drug interactions. Logistic regression was applied to determine the odds ratio for the association between the age and number of drugs taken and the number of potential drug–drug interactions. Main outcome measure Incidence and type of pDDIs in geriatric heart failure patients. Results A retrospective study was conducted by reviewing the medical records of 248 selected heart failure patients for the prescribed medicines for a 1-year period (January 2015–December 2015). The total number of potential drug–drug interactions was 1532, or approximately 6.28 (± 4.72 SD) per one person. The range of prescribed drugs was between three and fourteen, 92% of them have been taking more than five medicines, an average of 7.12 (± 2.07 SD) per patient. The average age was 72.35 (± 10.16 SD). The results have shown stronger association between the number of drugs taken (more than 7) and the occurrence of potential drug–drug interactions (more than 10)—37.84 (95% CI 9.012–158.896, P ≤ 0.001). No statistically significant differences were found between age and occurrence of potential drug–drug interactions (more than 10)—1.008 (95% CI 0.441–2.308, P = 0.848). Conclusion The incidence of drug-drug interactions in heart failure patients is high. The clinical pharmacist, as a part of the multidisciplinary team, could reduce medication-related problems, such as drug interactions, and to optimize drug therapy by checking the treatment prescribed at the discharge of these patients.
- Open Access
- 25 July 2019
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Pharmacy and Pharmaceutical Sciences
- p. 37-41
POTENTIAL DRUG-DRUG INTERACTIONS IN HEART FAILURE PATIENTS
Objective: The aim of the present study was to assess the prevalence, risk rating and the severity of hazardous pDDIs (potential drug-drug interactions) in the prescribed pharmacotherapy in the hospital discharged heart failure (HF) patients, primarily with co-administered drugs with narrow therapeutic index (statins, anticoagulants, antithrombotic drugs). Methods: The prescriptions of chronic heart failure patients for one year (January-December 2014) were analyzed for pDDIs through Lexi-interact® software. DDIs belonging to the categories D (Consider therapy modification) and X (Avoid combination) and/or severity of drug interaction-major, were selected for the study. Results: After reviewing the medical records of 985 patients, 239 patients were selected based on the criteria mentioned above. The average number of prescription drugs at hospital discharge was 7.27 medications (±1.84 SD) per patient. The total number of pDDIs was 1483 or approximately 6.2 (±3.89 SD) pDDIs per patient. With respect to the risk rating, in categories D and X were detected 76 (5.12 %) and 2 (0.13 %) pDDI, respectively. The major pDDIs were 108 (7.28 %). Conclusion: HF patients are at high risk of pDDIs. Screening of prescriptions for pDDIs and monitoring of pharmacotherapy in terms of response and associated adverse drug events will contribute to patient safety.
- 25 July 2019
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Pharmacy and Pharmaceutical Sciences
- p. 37-41
Open AccessPOTENTIAL DRUG-DRUG INTERACTIONS IN HEART FAILURE PATIENTS
Objective: The aim of the present study was to assess the prevalence, risk rating and the severity of hazardous pDDIs (potential drug-drug interactions) in the prescribed pharmacotherapy in the hospital discharged heart failure (HF) patients, primarily with co-administered drugs with narrow therapeutic index (statins, anticoagulants, antithrombotic drugs). Methods: The prescriptions of chronic heart failure patients for one year (January-December 2014) were analyzed for pDDIs through Lexi-interact® software. DDIs belonging to the categories D (Consider therapy modification) and X (Avoid combination) and/or severity of drug interaction-major, were selected for the study. Results: After reviewing the medical records of 985 patients, 239 patients were selected based on the criteria mentioned above. The average number of prescription drugs at hospital discharge was 7.27 medications (±1.84 SD) per patient. The total number of pDDIs was 1483 or approximately 6.2 (±3.89 SD) pDDIs per patient. With respect to the risk rating, in categories D and X were detected 76 (5.12 %) and 2 (0.13 %) pDDI, respectively. The major pDDIs were 108 (7.28 %). Conclusion: HF patients are at high risk of pDDIs. Screening of prescriptions for pDDIs and monitoring of pharmacotherapy in terms of response and associated adverse drug events will contribute to patient safety.
- Open Access
- 14 March 2019
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 25 (1) , 2406-2413
ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY OF MONOTERPENOID MYRTENAL IN RODENTS
- 14 March 2019
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 25 (1) , 2406-2413
Open AccessANALGESIC AND ANTI-INFLAMMATORY ACTIVITY OF MONOTERPENOID MYRTENAL IN RODENTS